annamycin has been researched along with Breast Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Booser, DJ; Esparza-Guerra, L; Esteva, FJ; Hortobagyi, GN; Priebe, W; Rivera, E; Valero, V | 1 |
| Andreeff, M; Doyle, LA; Ling, YH; Neamati, N; Perez-Soler, R; Priebe, W; Schneider, E; Zou, Y | 1 |
| Abolafio, G; Bertoli, G; Daidone, MG; Orlandi, L; Zaffaroni, N | 1 |
1 trial(s) available for annamycin and Breast Neoplasms
| Article | Year |
|---|---|
Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Liposomes; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged | 2002 |
2 other study(ies) available for annamycin and Breast Neoplasms
| Article | Year |
|---|---|
Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide.
Topics: Antibiotics, Antineoplastic; ATP-Binding Cassette Transporters; Blotting, Western; Breast Neoplasms; Carcinoma, Small Cell; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fluorescent Antibody Technique, Indirect; Humans; Immunohistochemistry; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1997 |
Effects of liposome-entrapped annamycin in human breast cancer cells: interference with cell cycle progression and induction of apoptosis.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Doxorubicin; Drug Carriers; Humans; Liposomes; Tumor Cells, Cultured | 2001 |